Xenon Pharmaceuticals Inc. (XENE) Stock Price & Analysis
Xenon Pharmaceuticals Inc. (XENE) fell 1.08% to USD 59.75 as of September 8, 2026 at 10:54 UTC, according to Nexqual real-time market data.
XENE last closed at USD 60.4; the session ranged USD 59.43–60.36 on volume of 459,231 shares. Market capitalization is $5.79B, with a 52-week range of USD 35.6–72.66 (NGM). Source: Nexqual, September 8, 2026 at 10:54 UTC.
Key Statistics (as of September 8, 2026 at 10:54 UTC)
| Price | USD 59.75 |
|---|---|
| Change | ▼ 1.08% (down) |
| Previous Close | USD 60.4 |
| Open | USD 60.02 |
| Day Range | USD 59.43 – 60.36 |
| 52-Week Range | USD 35.6 – 72.66 |
| Volume | 459,231 shares |
| Market Cap | $5.79B |
| Exchange | NGM |
Technical Analysis (XENE)
Nexqual's technical model rates XENE "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 10:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.78 (neutral) |
| vs SMA50 | Below (USD 63.54) |
| MACD | -0.86 (negative) |
Analyst Ratings (XENE)
Wall Street analysts rate XENE "Strong Buy" based on 19 analysts, with a mean price target of USD 81.3 (range USD 69–100), per Nexqual as of September 8, 2026 at 10:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 81.3 |
| High Target | USD 100 |
| Low Target | USD 69 |
| Buy / Hold / Sell | 20 / 0 / 0 |
Earnings (XENE)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -1.16 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.11 vs est -1.16 ▲ beat |
| 2026-03-31 | USD -1.17 vs est -1.2 ▲ beat |
| 2025-12-31 | USD -1.31 vs est -1.21 ▼ miss |
| 2025-09-30 | USD -1.15 vs est -1.16 ▲ beat |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Financials & Fundamentals (XENE)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -43.62% |
| Debt / Equity | 0.52 |
| Current Ratio | 21.02 |
| Total Cash | $930.69M |
| Total Debt | $6.42M |
| Free Cash Flow | $-203.55M |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Financial Health Score (XENE)
Nexqual rates Xenon Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 10:54 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $931M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$204M, burning cash |
| Efficiency | Critical — ROE -44%, ROA -28.0% |
Ownership (XENE)
| Insider Ownership | +0.11% |
|---|---|
| Institutional Ownership | +107.68% |
| Shares Outstanding | 96.84M |
| Float | 90.95M |
| Short % of Float | +5.86% |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Leadership (XENE)
Xenon Pharmaceuticals Inc. is led by Ian C. Mortimer C.M.A. (age 49), President, CEO & Director, per Nexqual as of September 8, 2026 at 10:54 UTC.
| President, CEO & Director | Ian C. Mortimer C.M.A. (age 49) |
|---|---|
| Chief Financial Officer | Thomas Patrick Kelly (age 54) |
| Chief Operating Officer | Matthew D. Ronsheim (age 53) |
| Executive Vice President of Human Resources | Shelley McCloskey B.A. (age 65) |
| Executive Vice President of Strategy & Innovation | Robin P. Sherrington (age 64) |
Major Backers & Investors (XENE)
Notable institutional backers of Xenon Pharmaceuticals Inc. include FMR, LLC, Avoro Capital Advisors LLC, Polar Capital Holdings PLC, according to Nexqual as of September 8, 2026 at 10:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 9.98% |
| Avoro Capital Advisors LLC | 5.98% |
| Polar Capital Holdings PLC | 4.73% |
| Driehaus Capital Management, LLC | 4.57% |
| T. Rowe Price | 4.49% |
| Jupiter Topco LLC | 4.33% |
| Fidelity | 4.12% |
| JPMorgan | 3.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.33% |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
From Xenon Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our product candidates that are in clinical development may compete with various therapies and drugs, both in the marketplace and currently under development.     12   If one or more of our proprietary or partnered product candidates is approved for the treatment of epilepsy, we anticipate that they could potentially compete with other anti-seizure medications, or ASMs, or one another.
- If one or more of our proprietary product candidates were approved for the treatment of MDD, we anticipate that they could potentially compete with other anti-depressant medications, or ADs.
- While we believe that our technology, development experience, scientific knowledge and drug discovery approach provide us with certain advantages, we face potential competition in our discovery and product candidate development efforts from many different approaches and sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.
Partnerships
- Pursuant to our collaboration with Neurocrine Biosciences, Neurocrine Biosciences controls the prosecution, maintenance and other matters relating to some of the patent portfolio for the selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors subject thereto, although we have a right to comment.
- Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | USD 145.72 | ▼ 0.25% |
| XNCR | Xencor, Inc. | USD 26.61 | ▼ 1.08% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.56 | ▼ 1.06% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 84.95 | ▲ 0% |
| KRYS | Krystal Biotech, Inc. | USD 358.24 | ▼ 2.98% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:54 UTC. This page is informational and not investment advice.